Glenmark Pharmaceuticals, USA (Glenmark) has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex 1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals.

Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy said, “We are pleased to bring to market a lower-cost alternative to

Bumex Injection, 0.25 mg/mL. This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”